Is Johnson & Johnson Stock Underperforming the Dow?

With a market cap of $394.2 billion, New Brunswick, New Jersey-based Johnson & Johnson (JNJ) is a global healthcare company with a diversified business model spanning pharmaceuticals, medical devices, and consumer health products. Its two main segments, Innovative Medicine and MedTech, offer a wide range of products, from prescription drugs in immunology, oncology, and infectious diseases to medical devices for surgery, orthopedics, and cardiovascular care.

Companies valued at $200 billion or more are generally considered “mega-cap” stocks and Johnson & Johnson fits this criterion perfectly. The company invests heavily in research and development, maintaining one of the largest R&D budgets in the pharmaceutical industry. J&J’s consumer health division includes well-known brands in baby care, skin health, oral care, and over-the-counter medicines.